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Design, Synthesis, and Evaluation of Gluten
Peptide Analogs as Selective Inhibitors
of Human Tissue Transglutaminase
which is also known to be the major focus of the autoan-
tibody response in Celiac Sprue [8]. Moreover, TG2-
mediated deamidation of these gluten peptides has
been shown to specifically increase their affinity to the
disease-associated HLA-DQ2 molecules, thereby en-
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Tampere University Hospital by TG2-mediated deamidation of gluten peptides [2].
Tampere, FIN-33014 Although the precise molecular details of this interaction
Finland in vivo remain to be eludicated, selective inhibition of
TG2 in the small intestine might represent a therapeuti-
cally useful strategy for countering the immunotoxic re-
Summary sponse to dietary gluten in Celiac Sprue patients [9,
10]. The attractiveness of this proposal is supported by
Recent studies have implicated a crucial role for tissue recent reports that transgenic mice in which the TG2
transglutaminase (TG2) in the pathogenesis of Celiac gene is inactivated are viable, phenotypically normal,
Sprue, a disorder of the small intestine triggered in and born with the expected Mendelian frequency [11,
genetically susceptible individuals by dietary exposure 12]. Of particular interest is the proteolytically resistant
to gluten. Proteolytically stable peptide inhibitors of consensus sequence PQPQLPY found in many gluten
human TG2 were designed containing acivicin or alter- proteins that is both an exceptionally good substrate of
natively 6-diazo-5-oxo-norleucine (DON) as warheads. human TG2 [13, 14] and also part of the major immuno-
In biochemical and cell-based assays, the best of dominant epitopes in gluten [4, 5, 7].
these inhibitors, Ac-PQP-(DON)-LPF-NH2, was consid- TG2 is a member of the transglutaminase family of
erably more potent and selective than other TG2 inhibi- enzymes that play important roles in diverse biological
tors reported to date. Selective pharmacological inhi- functions by selectively crosslinking proteins via -glu-
bition of extracellular TG2 should be useful in exploring taminyl isopeptide bonds [15]. Aberrant TG2 activity is
the mechanistic implications of TG2-catalyzed modifi- believed to play a role in neurological disorders such
cation of dietary gluten, a phenomenon of consider- as Alzheimer’s, Parkinson’s, and Huntington’s disease
able relevance in Celiac Sprue. [16]. A variety of compounds have been used to sup-
press TG2-catalyzed protein crosslinking [17, 18]. How-
Introduction ever, since several of these compounds contain primary
amines in addition to potential inhibitory motifs, it re-
Celiac Sprue is a disorder of the small intestine induced mains unclear whether the observed effects are due to
by dietary exposure to gluten proteins from common an excess of competing amine donor or by blocking
food grains such as wheat, rye, and barley. Ingestion TG2 turnover. More recently, several mechanism-based
of such proteins produces flattening of the normally active site inhibitors of guinea pig TG2 have been de-
luxurious, rug-like, epithelial lining of the small intestine
scribed by Keillor and coworkers [19–21]. These inhibi-
and in turn leads to clinical symptoms including fatigue,
tors were analogs of the widely used TG2 substrate,
chronic diarrhea, malabsorption of nutrients, weight
benzyloxycarbonyl-glutamyl-glycine (Cbz-Gln-Gly). The
loss, abdominal distension, anemia, as well as a sub-
contribution of the peptide scaffold to inhibitor potencystantially enhanced risk for the development of osteopo-
and selectivity remains to be explored. Moreover, therosis and intestinal malignancies (lymphoma and carci-
effects of these inhibitors on human TG2 or other TG2-noma). In spite of the wide prevalence of the disease
like mammalian enzymes have not been evaluated in(1:200 in most of the world’s population groups), no
vitro or in cell based assays.therapeutic agents have been developed for this dis-
We observed that the specificity of human TG2 forease, and the only known treatment is a strict, lifelong
immunogenic gluten peptides correlates well with thegluten-free diet [1–3].
ground state affinity (KM) between the enzyme and sub-Recent reports have identified several short proline-
strates [13]. Moreover, these high-specificity glutenand glutamine-rich sequences from wheat gluten that
peptides share a type II polyproline helical conformationactivate gluten-responsive T cells from Celiac patients
[22]. Finally, we also observed that these peptides arebut not from control individuals in an HLA-DQ2 (or DQ8)-
remarkably resistant toward proteolysis by gastric, pan-dependent manner [4–7]. Importantly, most of these
creatic, and intestinal brush border proteases [23]. To-peptides are also substrates of the enzyme tissue transglu-
gether, these observations have led us to design andtaminase (transglutaminase 2; tTGase; TG2, EC 2.3.2.13),
evaluate analogs of these peptides as highly selective
mechanism-based inhibitors of human TG2. Such inhibi-*Correspondence: ck@chemeng.stanford.edu
tors could have similar pharmacokinetic and tissue dis-5 Present address: ESBATech AG, Wagistr. 21, CH-8952 Zurich-
Schlieren, Switzerland. tribution properties as pathogenic gluten peptides, and
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Figure 1. Reactive Glutamine Isosteres and
Their Gluten Peptide Analogs
Three different reactive isoteres of glutamine
were evaluated as potential inhibitors of hu-
man tissue transglutaminase. The reactive
moieties are shaded.
might therefore be valuable probes of Celiac Sprue gether with varying amounts of the substrate Cbz-Gln-
Gly (KM  5.9 mM). The inhibition parameters were ob-pathogenesis.
tained by progress curve analysis [27] using a continu-
ous glutamate dehydrogenase coupled assay [28]. AsResults
summarized in Table 1, derivatization of acivicin by the
flanking PQP and LPY tripeptides increased its specific-
Design, Synthesis, and In Vitro Evaluation
ity (kinh/KI) 100-fold compared to unmodified acivicin.of Selective Inhibitors of Human TG2
This result demonstrated that high-affinity peptide se-
We sought to replace the reactive glutamine (underlined)
quences could be exploited to enhance the specificity
of the high-affinity TG2 substrate, PQPQLPY [13], with of small molecule inhibitors of human TG2. However,
reactive glutamine isosteres shown in Figure 1. We first comparison with the kinetic parameters of unmodified
evaluated analogs containing a tetramethyl thioimida- glutamine as a TG2 substrate versus PQPQLPY revealed
zolyl moiety. A prototype compound of this class, that the large difference in substrate specificity [(kcat/L682777 (2a, Figure 1), is one of the most potent inhibi- KM)Gln 104 (kcat/KM)PQPQLPY] was only partially reflectedtors of the transglutaminase family of enzymes [24], in- in the observed difference in inhibitor specificity [(kinh/cluding human TG2, as demonstrated in this study (kinh/ KI)Aci  0.01  (kinh/KI)PQPAciLPY].KI 1.4 min1 mM1). We therefore introduced this com- A possible reason for the suboptimal cooperativity
pound in place of the -carbonyl group of glutamine between acivicin and the flanking peptides could be
embedded in a low-affinity Cbz-X-OMe and a high-affin- that the constrained dihydro isoxazole ring assumes an
ity AcPQPELPYPQP-X-LPY scaffold. The specificity of unfavorable conformation upon binding to the active
the resulting tetramethyl thioimidazolium inhibitors 2b site that cannot be alleviated as efficiently in the context
and 2c was reduced compared to L682777 (data not of the peptide as compared to free acivicin. Indeed,
shown), in part because of weaker binding to the TG2 earlier studies on the carbonyl amide donor require-
active site. This decrease in specificity suggests that ments of guinea pig TG2 indicated a preference for an
the carbonyl group of L682777 might be positioned quite unsubstituted extended -CH2-CH2- chain adjacent to the
differently in the active site of human TG2 than the carbonyl amide [17]. To address this possibility, the un-
-carbonylamide group of a reactive glutamine in TG2 branched 6-diazo-5-oxo-norleucine was incorporated
substrates. into a low-affinity scaffold, yielding Cbz-DON-OMe 4b,
We therefore considered the naturally occurring gluta- and a high-affinity scaffold, yielding Ac-PQP-DON-LPF-
mine analogs acivicin (Aci) 3a and 6-diazo-5-oxo-norleu- NH2 4c. (Relative to PQPQLPY, N-terminal acetylation,
cine (DON) 4a, both originally isolated as antibiotics from C-terminal amidation or a Y→F substitution do not have
Streptomyces strains. Both amino acids are bona fide a significant impact on kcat or KM [Table 1]). To avoid
glutamine isosteres, as judged by their potent inhibition cyclization of the -glutamyl moiety, the N-Cbz-5-oxa-
of -glutamyl transpeptidase (-gTP, EC 2.3.2.2) [25]. zolidinone-protected glutamate was activated by thionyl
-gTP is structurally and mechanistically related to TG2, chloride and reacted with diazomethane [29] yielding 4b
and also catalyzes a similar transamidation reaction. In by subsequent methanolysis (Figure 2B). Activation of
addition the diazoketone moiety present in DON is a the central glutamate in Ac-PQPELPF-NH2 as a mixed
well-established inhibitory motif of cysteine proteases anhydride followed by treatment with diazomethane
[26]. At high concentrations ( 100 mM), both acivicin provided 4c after HPLC purification (Figure 2C).
and DON inactivated human TG2, suggesting their po- Notably, the second-order inactivation constants (kinh/
tential use as “warheads” in an appropriate high-affinity KI) were 4500-fold and 1.5  107 -fold higher for 4b and
peptide context (Table 1). 4c, respectively, compared to unmodified DON (Table
To test this hypothesis, commercially available acivi- 1). As shown in Figure 3A, 4c rapidly inactivates TG2 at
cin was protected with the fluorenyl-methoxycarbonyl a concentration of 1 M even in the presence of a high
(FMOC) group and incorporated into the PQP-Aci-LPY substrate concentration ([S]  10 KM). The inactivated
3b sequence by standard automated solid phase pep- enzyme could not be reactivated even after overnight
tide synthesis (Figure 2A). The HPLC-purified product incubation in the absence of free inhibitor or in the pres-
ence of an alternative nucleophile amine donor such aswas incubated with recombinant human TG2 [13] to-
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Table 1. Kinetic Parameters of Catalysis and Inhibition of Tissue Transglutaminase by Reactive Glutamine Peptide Analogs
Reactive Motif Gln Aci DON
kcat KM kcat/KM kinh KI kinh/KI kinh KI kinh/KI
Scaffold [min1] [M] [min1M1] [min1] [M] [min1M1] [min1] [M] [min1M1]
H-X-OH – 0.2 	 2 0.015 0.087 0.17 0.025 0.13 0.2
Cbz-X-OMe – 0.03 90 – – – 0.12 1.35  104 890
PQP-X-LPY 28a 3  104a 9.3  104a 0.014 7.8  104 18 – – –
Ac-PQP-X-LPF-NH2 40 4  104 9.7  104 – – – 0.2 7  108 2.9  106
The reactive glutamine (-X-) in the peptide substrate was substituted by the inhibitory residue acivicin (Aci) or 6-diazo-5-oxo-norleucine (DON).
Catalytic parameters for deamidation of glutamine-containing analogs were obtained via a coupled NADH/glutamate dehydrogenase assay.
Inhibitory constants for acivicin and 6-diazo-5-oxo-norleucine were obtained by progress curve analysis using varying amounts of the reference
substrate Cbz-Gln-Gly.
aAdopted from reference [13].
Ac-Lys-OMe (data not shown), suggesting this inhibition the Cbz- and methoxy-protection apparently reversed
the preference of the DON warhead from -gTP to TG2,to be either irreversible or slow and tight binding. The
relative specificity (kinh/KI) of inhibitors 4a, 4b, and 4c resulting in a relative selectivity of (kinh/KI)TG2/(kinh/KI)-gTP
 3  104 for Cbz-DON-OMe 4b. A similar reversal incorrelated well with the relative specificity (kcat/KM) of
TG2 for the corresponding substrates 1a, 1b, and 1c selectivity was found for Ac-PQP-DON-LPF-NH2 4c.
These results are consistent with the known specificity(Table 1). As predicted, the enhanced specificity of the
DON-containing peptides was primarily due to lower KI of -gTP [30, 31], and suggest that DON-containing pep-
tide inhibitors may have the necessary specificity to bevalues; the first-order inactivation constant (kinh) re-
mained relatively unchanged for 4a, 4b, and 4c. Finally, effective in cell-based and in vivo assays.
in agreement with the design of isosteric analogs, TG2
inhibition by Cbz-DON-OMe 4b was competitive with Evaluation of TG2 Inhibitors in a Model
for Enterocyte Differentiationrespect to the reference Cbz-Gln-Gly substrate (Figure
3B). Together, these observations demonstrated that As a final test of the potential utility of these inhibitors
as probes of the role of TG2 in intestinal biology, anthe diazoketone moiety of DON is an excellent isostere
of glutamine in the active site of human TG2. assay for differentiation of human T84 epithelial cells in
three-dimensional collagen gel cultures containing IMR-
90 fibroblasts was used [32, 33]. In this assay, T84 cellsSelectivity of DON-Containing Peptide Inhibitors
It was also anticipated that conversion of DON into pep- are cultured within type I collagen gel together with
fibroblasts without cell-to-cell contact. In such a cocul-tidic derivatives would alter the specificity of this war-
head for other competing enzymes that are likely to be ture model for enterocyte differentiation, a majority of
T84 colonies organize into luminal formations with well-present in the celiac gut under physiological conditions.
For example, whereas the related enzyme -glutamyl deposited basement membranes, as well as morpholog-
ically and enzymatically mature brush border mem-transpeptidase (-gTP) was efficiently inactivated by
free DON 4a with a second-order rate constant (kinh/ branes. Dose-dependent inhibition of differentiation was
observed by both L682777 and Ac-PQP-(DON)-LPF-NH2KI)DON 120 min1M1, its inactivation by Cbz-DON-OMe
4b reduced to (kinh/KI)Cbz-DON-OMe  0.03 min1mM1. Thus, over a range of 1–100 M and 0.1–10 M inhibitor con-
Figure 2. Synthesis of Protected or Peptide-
Bound Reactive Glutamine Isosteres
For details, see Experimental Procedures.
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Figure 3. Irreversible Inhibition of Tissue
Transglutaminase by 6-Diazo-5-Oxo-Norleu-
cine-Containing Compounds
(A) Progress curve analysis of tissue transglu-
taminase incubated with 1 M Ac-PQP-DON-
LPF-NH2 4c and 45 mM (closed squares), 60
mM (closed triangles), 90 mM (open circles),
or 120 mM (closed circles) of the substrate
Cbz-Gln-Gly. Incubation with 45 mM Cbz-Gln-
Gly alone without inhibitor (open squares).
Inset: progress curves were nonlinear least-
squares fitted, as described in the Experi-
mental Procedures section, to calculate the
inhibition constants.
(B) Double-reciprocal plot of competitive inhi-
bition of tissue transglutaminase by Cbz-DON-
OMe 4b. Initial velocities (v0) of Cbz-Gln-Gly
deamidation in the presence of the indicated
amounts of this inhibitor were obtained by
nonlinear least-squares fitting of the corre-
sponding progress curves.
centrations, respectively (Figure 4). In the same concen- also reminiscent of the effect of anti-TG2 autoantibodies
from Celiac Sprue patients on T84 differentiation [33]tration range for both inhibitors tested, significant cyto-
toxicity was neither observed toward T84 cells nor and suggest that the primary target of the peptide inhibi-
tor is extracellular TG2. It should be noted that althoughfibroblasts. These findings are in contrast with other
nonspecific small molecule TG2 inhibitors tested (T.H., enterocyte differentiation is inhibited in this assay, pre-
sumably this arises due to inactivation of TG2 on bothunpublished data), such as cystamine dihydrochloride
[34] or factor XIIIa fragment 72–97 [35]. Our results are the mucosal and serosal sides of enterocytes. In con-
Figure 4. Inhibition of T84 Human Intestinal
Epithelial Cell Differentiation
Inhibition of T84 differentiation was per-
formed on cells from 11 days cultures and is
expressed as percent differentiated T84 cell
colonies relative to an equivalent DMSO con-
trol. The columns represent the average of
three independent sets of experiments with
two replicates, and the bars represent the
standard deviations.
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1H (CDCl3, 200 MHz)  4.06 SCH2C(O) (2H, s); 3.53 CH3N (6H, s);trast, serosal side TG2 in the intact intestine is inaccessi-
1.86 CH3C (6H, s); 1.83 C(O)CH3 (3H, s). 13C (CDCl3, 200 MHz) ble to both peptide substrates and inhibitors, and should
200.3, 135.3, 128.5, 45.1, 33.3, 28.2, 8.6.be able to facilitate normal enterocyte differentiation.
m/z (ESI)  213.1 (100%)[M-Cl]
; 460.7 (10%)[2M-Cl]
.
Further animal studies with these inhibitors could help
address the role of TG2 localization in differentiation of Synthesis of Compound 2b
the small intestinal epithelium. 3.7 g (15.5 mmol) of 2-N-benzyloxycarbonyl-diamino propionic acid
(Cbz-Dap-OH, Bachem) in 35 ml methanol was carboxymethylated
by treatment with 10 ml trimethylsilyl chloride overnight at roomSignificance
temperature. Solvent and excess reactant were removed by rotary
evaporation, and the product was recrystallized from methanol to
In this study, acivicin and especially 6-diazo-5-oxo- yield 3.5 g (80%) of pure, dry Cbz-Dap-OMe (m/z  253.1). To 0.98
g (3.9 mmol) of the latter intermediate resuspended in 15 ml drynorleucine (DON) were identified as potent inhibitory
acetonitrile and 0.95 ml triethylamine was added 0.95 g (3.4 mmol)motifs of human TG2. The excellent molecular mimicry
bromoacetic acid anhydride and 10 mg 4-dimethylaminopyridine.of glutamine by DON in the active site of TG2 facilitated
After stirring for 2 hr, the solvent was removed by rotary evaporation.the conversion of proteolytically stable high-affinity
The resulting residue was dissolved in ethyl acetate and extracted
TG2 substrates into selective inhibitors in a predict- with 2 vol each of aqueous saturated solutions of NaHCO3, NaHSO4,
able manner. The best inhibitor in this series, Ac-PQP- and NaCl. The organic phase was concentrated and recrystallization
from isopropanol:hexane yielded 0.43 g (35%) of the desired 3-N-DON-LPF-NH2, is capable of inactivating 90% of TG2
bromoacetyl-2-N-Cbz-propionic acid methyl ester [Cbz-Dap(AcBr)-activity within 20 min at submicromolar concentra-
OMe]. 285 mg (0.75 mmol) of this compound and 120 mg (0.77 mmol)tions. (At higher concentrations complete inhibition
of 1-thio-2,3,4,5-tetramethyl-imidazole [36] in 1 ml chloroform wascan be achieved in shorter times.) It has substantially
stirred overnight at room temperature. The raw product was concen-
greater selectivity toward TG2 as compared to similar trated purified by silica gel flash chromatography with CHCl3:
enzymes such as-glutamyl transpeptidase. Addition- MeOH:TFA (9:1:0.1) as eluent yielding 490 mg of 2b as a red glass-
like substance after drying in vacuo.ally, the absorption and tissue-level distribution prop-
Rf (CHCl3:MeOH:TFA  9:1:0.1)  0.09erties of such gluten-like inhibitors are likely to re-
1H (d6 -DMSO, 500 MHz)  8.52 NH (1H, t, J  5.5 Hz); 7.72 NHsemble those of the inflammatory gluten peptides
(1H, d, J  8.5 Hz); 7.35 ArH (5H, m); 5.05 ArCH2 (2H, s); 4.15 -CHthemselves. As such, it may be possible to “follow the
(1H, m); 3.75 NCH3 (6H, s); 3.63 SCH2 and OCH3 (5H, s); 3.49–3.5
gluten trail” in the preferential targeting of oral gluten -CH (1H, m); 3.25–3.27 -CH (1H, m); 2.29 NCH3 (6H, s).
analogs to intestinal TG2. We note that, although an 13C (d6 -DMSO, 500 MHz) 171.5, 168.1, 156.7, 137.4, 136.8, 129.9,
129.1, 128.5, 74.4, 66.4, 54.1, 52,8, 37.6, 34.1, 9.4.enteric coating would be required to insulate DON-
m/z (ESI)  449.3 (100%) [M]
.containing inhibitors from the acidic environment of
the stomach, the inhibitors should be stable in the
Synthesis of Compound 2cneutral pH environment of the small intestine. And
Ac-PQPELPYPQP-Dap-LPY was synthesized by solid phase pep-
finally, at micromolar concentrations, they can effec- tide synthesis using Fmoc-Dap(Boc)-OH (Bachem) to introduce the
tively inhibit TG2-mediated differentiation of T84 cells, diaminopropionic acid residue. 110 mg (66 mol) of the deprotected
an established model of intestinal enterocyte matu- HPLC-purified peptide were dissolved in 660l of a 1M triethylamine
bicarbonate buffer (Fluka) and reacted with 400 l of a 1 M solutionration.
of bromoacetic acid N-hydroxysuccinimide ester in DMF at 4C.TG2 inhibitors that mimic proteolytically stable glu-
After 2 hr, the reaction was quenched by addition of 80 l of TFA,ten peptides may not only be useful chemical probes
and the bromoacetylated intermediate was purified by reverse
of the the role of extracellular TG2 in small intestinal phase HPLC using a water: acetonitrile: 0.1% TFA gradient. Lyophili-
biology but also in establishing the precise role of TG2 zation of the major product eluting at 31% acetonitrile yielded 33.5
in Celiac Sprue. Finally, since aberrant TG2 activity mg bromoacetylated peptide with a the expected max  275 nm,
mass isotope distribution and fragmentation pattern (m/z [M
H]
 has also been implicated in certain dermatological and
1786.3 [60%], 1787.3 [65%], 1788.5 [100%], 1749 [60%], 1790.3neurodegenerative disorders [15, 16], the inhibitors
[40%]).reported here might also serve as useful probes of the
28.3 mg of Ac-PQPELPYPQP-Dap(AcBr)-LPY was reacted over-
role of TG2 in these diseases. night with 26.2 mg (170 mol) 1-thio-2,3,4,5-tetramethyl-imidazole
[36] in 400 l CHCl3:DMF (1:1) at room temperature. The solvent
Experimental Procedures was concentrated by rotary evaporation, the peptide precipitated
by addition of ice-cold ether, and the resulting residue was purified
General by reverse phase HPLC using a water: acetonitrile: 0.1% TFA gradi-
All reagents for chemical synthesis were obtained from Aldrich (MO); ent. The product 2c eluting at 32.5% acetonitrile was lyophilized
all reagents and enzymes for biochemical assays were from Sigma yielding 16.2 mg (8.7 mol) with an 269max  9,600 M1 cm1.
(MO). Peptides were synthesized by the Stanford Protein and Nu- LC-MS: m/z [M]
  1862.9 (70%), 1863.8 (100%), 1864.8 (50%),
cleic Acid facility on a Perkin Elmer/ABI 433A using standard HBTU- 1865.9 (15%).
coupling/TFA deprotection and purified by preparative reversed
phase HPLC on a Beckman Ultrasphere C18 column (15 2.54 cm). Synthesis of Fmoc-Acivicin
NMR spectra were acquired on a Varian Gemini-200 or Varian Inova- 3.1 ml of a 0.75 M solution of Fmoc-N-hydroxysuccinimide in ace-
500 with tetramethylsilane as a standard. tone were added to 0.4 g acivicin (L-(S,5S)--amino-3-chloro-4,5-
dihydro-5-isoxazole acetic acid, 2.25 mmol; Biomol, PA) dissolved
in 3.1 ml of a 10% Na2CO3 aqueous solution. The slurry was stirredSynthesis of 1,3,4,5-Tetramethyl-2-[(2-
Oxopropyl)thio]imidazolium Chloride (L682777) 2a for 1 hr at room temperature, and the pH was maintained at 9.0 by
addition of Na2CO3. The solvent was removed by rotary evaporation,0.5 g (3.2 mmol) of 1-thio-2,3,4,5-tetramethyl-imidazole [36] in 3
ml chloroform was reacted with 300 l (3.75 mmol) chloroacetone the residual solid was dissolved in 0.6 M HCl, extracted with ethyl
acetate, and the combined organic phases were concentrated to aovernight at room temperature. After rotary evaporation, recrystalli-
zation from 10 ml isopropanol:hexane (1:1) yielded 0.65 g (2.6 mmol, yellow oil. Recrystallization from ethyl acetate: hexane yielded 0.62
g (1.55 mmol, 70%) of the desired product as white crystals.70%) of dry, white needles. mp  177C.
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Rf (CH2Cl2: iPrOH: AcOH  100: 3: 1)  0.3 1 mM EDTA, 10 mM -ketoglutarate, 18 U/ml glutamate dehydroge-
nase (Biozyme, CA), 0.4 mM NADH, 3.3% DMSO, 0.5 M TG2, and1H (d6 -acetone, 200MHz)  7.87 ArH (2H, d, J  7.4 Hz); 7.73 ArH
(2H, d, J  7 Hz); 7.28–7.48 ArH (4H, m); 7.17 NH (1H, d, J  8 Hz); the indicated amount of substrate. The reaction of the prewarmed
and equilibrated components was started by addition of TG2 and5.22 -CH (1H, m); 4.66 -CH (1H, dd, J1  8.7 Hz, J2  4.5 Hz);
4.2–4.4 (3H); 3.6–3.4 (2H). was monitored spectrophotometrically by following the NADH con-
sumption at 340 nm (340  6220 cm1M1) and 30C from 2.5 to 2513C (d6 -acetone, 200 MHz)  213.4, 207.7, 145.1, 128.6, 128.0,
126.2, 120.9, 82.9, 67.6, 56.9, 47.9, 41.0. min. Measurements were performed in duplicate using 2, 5, 10, and
20 mM Cbz-Gln-Gly as a sodium salt, 19–150 mM glutamine, 1–10m/z (ESI)  401.3 (40%) [M
H]
, 423.4 (100%) [M
Na]
, 424.2
(90%) [M
Na]
, 425.3 (35%) [M
Na]
. mM Cbz-Gln-OMe (Bachem), or 0–1.2 mM Ac-PQPQLPF-NH2.
Synthesis of Pro-Gln-Pro-Aci-Leu-Pro-Tyr 3b Inhibition of TG2
PQPAciLPY was assembled by standard Fmoc solid phase chemis- In order to quantify inhibition of human TG2 by acivicin 3a (50 mM),
try using Fmoc-acivicin and commercially available building blocks PQPAciLPY 3b (0.45 mM), or Cbz-DON-OMe 4b (0, 0.08, 0.25, or 0.75
in a 25 mol scale on a Symphony/Multiplex automated peptide mM), the enzyme was incubated with appropriate concentrations of
synthesizer. After cleavage/deprotection with TFA, preparative re- the inhibitors in the TG2 reaction buffer (above). After 2.5 min NADH
verse phase HPLC on a Beckman Ultrasphere C18 column (15  consumption was monitored in the presence of 2, 5, 10, or 20 mM
2.54 cm) with a water: acetonitrile: 0.1% TFA gradient yielded 4 Cbz-Gln-Gly·Na. The progress curves were fitted to the following
OD275 (3.4 mol, 14% yield based on one tyrosine with 272  1200 equation which describes product formation as decrease of absorp-
cm1M1) of the desired peptide. The product eluted at 24.5% aceto- tion at   340 nm with simultaneous exponential decay of enzyme
nitrile. as modified from [27]: Abs  Abs0  v0· 6.22 mM1 ·(1-ekt)/k.
LC-MS: [M
H]
 874.6 g/mol. Substrate dependence of v0 and k yielded the kinetic parameters
kinh and KI. Inactivation by Ac-PQP-DON-LPF-NH2 4c (1 M) was
Synthesis of Cbz-DON-OMe 4b measured at 0.3 M TG2 in the presence of 45, 60, 90, and 120 mM
6 g (20 mmol) S-(
)-3-benzyloxzcarbonyl-5-oxo-4-oxazolidine pro- Cbz-Gln-Gly·Na to compete efficiently with the inhibitor. Due to the
pionic acid in 37 ml ethanol-free chloroform was reacted with 1.8 high absorption of DON at   340 nm, inhibition of TG2 (25 M)
ml thionyl chloride for 3 hr at room temperature [29]. After rotary by free DON 4a (0, 30, 100, and 300 mM) was measured discontinu-
evaporation, the residual oil was diluted with additional chloroform, ously in 200 mM MOPS, pH  7.1, 5 mM CaCl2, 1 mM ETDA at 30C.
which was removed under reduced pressure. To the resulting oil, Residual activity of 20 l aliquots withdrawn at t  3–112 min were
dissolved at 0C in 15 ml THF, was added drop-wise a saturated, determined by dilution into 1 ml of assay buffer using 10 mM Cbz-
ethanol-free solution of diazomethane in ice-cold ether until gas Gln-Gly·Na. Inhibition by 0–8 M L682777 2a was determined with
formation ceased and an intense yellow color persisted. The latter 7.8 mM Cbz-Gln-Gly·Na.
solution was prepared fresh from diazald/KOH, as described by the
manufacturer (Aldrich). The solvent was removed by rotary evapora- Confirmation of Irreversible Inactivation
tion, and the residue was redissolved in methanol and refluxed 10 M TG2 in 200 mM MOPS, pH  7.1, 5 mM CaCl2, 1 mM EDTA,
for 10 min after addition of sodium bicarbonate. The solvent was 3.3% DMSO was treated with or without 25 M Ac-PQP-DON-LPF-
removed by rotary evaporation, and the resulting oil was extracted NH2 4c for 90 min at 30C. Successive gel filtration over a Pharmaciawith ethyl acetate and a saturated aqueous solution of sodium bicar- NAP-5 and PD-10 column equilibrated in the same buffer was used to
bonate. The pooled organic phases were dried over sodium sulfate, remove excess inhibitor. Residual TG2 activity in the resulting solutions
concentrated, and purified by silica gel flash chromatography with with or without initial inhibitor was measured after 150, 300, and 1000
hexane:ethyl acetate:triethylamine (1:1:0.01) as eluent. Additional
min at 30C. Additionally, a final concentration of 0.2 mM N-acetyl-
reverse phase HPLC purification on a Beckman Ultrasphere C18
lysine-methyl ester (Ac-Lys-OMe) was added after gel filtration, and
column (15  2.54 cm) with a water: acetonitrile: 0.1% ammonium
residual TG2 activity was measured after 75 and 1000 min.
hydrogen carbonate gradient provided 85 mg (0.26 mmol) of pure
product, eluting at 38.5% acetonitrile. The product was dried in
Inhibition of -glutamyl Transpeptidase (-gTP)vacuo.
Progressive inhibition of -gTP (type II from bovine kidney) by 0–25Rf (hexane: ethyl acetate: triethylamine  1: 1: 0.01)  0.2.
mM DON was assayed in 200 mM MOPS, pH  7.1, using 20 mM1H (d6 -DMSO, 500MHz)  7.77 NH (1H, d, J  9.6 Hz); ArH (2H,
Gly-Gly, 1 mM L--glutamyl-p-nitroanilide, for 15 min at 30C [25].d, J 7.4 Hz); 7.34-7.30 ArH (5H, m); 6.07 CHN2 (1H, s); 5.04 PhCH2O
The reaction was started by addition of -gTP to a final concentra-(3H, s); 4.08-4.01 -CH (1H, m); 3.63 OCH3 (3H, s); 2.40 -CH2 (2H,
tion of 40 U/l. Product formation of the liberated p-nitroanilidem); 1.97 -CH (1H, m), 1.78 -CH (1H, m).
(410  8,800 cm1 M1) was fitted to a competitive, exponentialm/z (ESI)  341.9 (100%)[M
Na]
; 314.1 (22%)[M
Na-N2]
.
inhibition [27].
220 U/l -gTP in 200 mM MOPS, pH  7.1, 5.5% DMSO wereSynthesis of Ac-Pro-Gln-Pro-DON-Leu-Pro-Phe-NH2 4c
treated with 0–5 mM Cbz-DON-OMe 4b for 1300 min at 30C. Resid-72 mg (8.3 mol) of HPLC-purified, lyophilized Ac-PQPELPF-NH2 in
ual -gTP activity was determined spectroscopically at 410 nm after1 ml THF and 15 l (135 mol) N-methyl morpholine were mixed
1:11 dilution with 1.1 mM L--glutamyl-p-nitroanilide corroboratingwith 13 l (100 mol) isobutyl chloroformate at 0C, immediately
linear concentration dependence. Similarly, treatment with 20 Mfollowed by addition of up to 0.5 mol of a saturated diazomethane
Ac-PQP-DON-LPF-NH2 4c for 1200 min resulted in 15% -gTP activ-solution in dry ether generated from Diazald as described by the
ity compared to uninhibited control.supplier. After 1 hr, the solvents were evaporated, the residual solid
was extracted with ethyl acetate and a 5% aqueous solution of
Inhibition of T84 Intestinal Cell DifferentiationNH4HCO3, and the combined aqueous phases were concentrated
The ability of Ac-PQP-(DON)-LPF-NH2 and L682777 to inhibit intesti-by rotary evaporation. The crude product was purified by semipre-
nal T84 epithelial cell differentiation was tested using a previouslyparative reversed phase HPLC on a Vydac 259VHP810 RP polymer
described three-dimensional epithelial-mesenchymal cell coculturecolumn (d  1 cm) using a 0.1 M triethylamine hydrogen carbonate
model [32]. This model has also been used to establish a role forbuffer (Fluka) with increasing percentage of acetonitrile as mobile
extracellular TG2 in this differentiation process through the use ofphase. The UV280-active fractions eluting at 18.9% acetonitrile were
anti-TG2 antibodies derived from Celiac Sprue patients [33]. Forpooled and lyophilized yielding 19.4 OD275 of HPLC-pure 4c (1.7
three-dimensional cocultures 5  105 T84 epithelial cells were sus-mol, based on an DON275  11,700 cm1M1 as determined for DON
pended in 1 ml of ice-cold type I collagen solution (8 vol) supple-(Bachem) in 10 mM Tris-HCl pH  8.5).
mented with 10 concentrated RPMI (1 vol) (GIBCO-BRL) and 7.5%m/z (ESI)  914.2 (100%) [M
Na]
; 886.5 (75%) [M
Na-N2]
.
NaHCO3 (1 vol) and layered onto Nunclon 24-well plates (Nunc,
Roskilde, Denmark). After a cell-free collagen layer fibroblast sus-Determination of TG2 Activity
pension (5 105 cells/ml) in 1:1 mixture of supplemented DMEM/F12TG2 was assayed routinely as described [13, 28], in a 1 ml or 150
l reaction mixture containing 200 mM MOPS pH 7.1, 5 mM CaCl2, (1:1) (GIBCO-BRL) and BME (GIBCO-BRL) were added and grown as
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